risankizumab IV
M16-067
Phase 3 small_molecule completed
Quick answer
risankizumab IV for Ulcerative Colitis (UC) is a Phase 3 program (small_molecule) at AbbVie with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie
- Indication
- Ulcerative Colitis (UC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed